---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122266"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:36:01.840920+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# RevMed Q3 net loss $156M; Phase 3 PDAC trial started, RMC-9805 initial data

## Summary
- Net loss of $156.3M for Q3 2024 vs. $108.4M in Q3 2023; R&D expenses rose to $151.8M.
- Cash, equivalents and securities were $1.55B as of Sept 30, 2024; funding projected into 2027.
- Phase 3 RASolute 302 trial of RMC-6236 in metastatic PDAC dosed first patient; data event-driven.
- Initial RMC-9805 (KRAS G12D inhibitor) data show encouraging safety and antitumor activity; 1200 mg once daily candidate Phase 2 dose.
- FY 2024 GAAP net loss guidance reiterated at $560M-600M; NSCLC and combination data due in Q4 2024.

## SEC filing metadata
- accession: 0000950170-24-122266
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000095017024122266/0000950170-24-122266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000095017024122266/rvmd-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122266
- JSON: https://secwatch.observer/filing/0000950170-24-122266.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122266.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.